ReviewFrontiers in immunology2021
Advances in Development and Application of Influenza Vaccines.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 95 citations in OpenAlex.
- Single-component self-assembling protein nanoparticles displaying stabilized prefusion-closed hemagglutinin trimers for influenza vaccine development.Nature communications · 2026Article
- mRNA Vaccines for Influenza: Hope for a Universal Vaccine?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Synthetic Biology Strategies for the Development of Live Attenuated Influenza Viruses: Recent Advances and Applications.Viruses · 2026Review
- Influenza B mosaic HA mRNA-LNP vaccines are cross-reactive and protective in mice.Molecular therapy. Nucleic acids · 2026Article
- Long-Term Immunogenicity and Protection of a rHVT-H9/Y280 Vaccine Against H9N2 Avian Influenza Virus in Commercial Layers with High Maternal Antibodies.Animals : an open access journal from MDPI · 2026Article
- Avian influenza and One Health: bridging animal and human health through integrated surveillance and vaccination.Frontiers in cellular and infection microbiology · 2026Review
- PB1 mutations as key drivers of influenza A virus evolution.Frontiers in microbiology · 2026Review
- Biological treatments for zoonotic salmonellosis: an evolving therapeutic landscape.Frontiers in microbiology · 2026Review
- Factors Influencing the Willingness of Layer Specialized Households to Participate in Cooperative Avian Influenza Prevention and Control: Evidence from China.Veterinary sciences · 2025Article
- Review
- Versatile and Scalable Nanoparticle Vaccine as a Scaffold Against Newly Emerging Influenza Viruses.Viruses · 2025Article
- Evaluation of the influenza vaccine protection in the house dust mite-induced chronic allergic asthma mice model and the evaluation of squalene oil in water emulsion as an adjuvant candidate.Respiratory research · 2025Article
- Avian influenza mRNA vaccine encoding hemagglutinin provides complete protection against divergent H5N1 viruses in specific-pathogen-free chickens.Journal of nanobiotechnology · 2025Article
- Article
- Research publications and global manufacture of veterinary vaccines against avian influenza A (2019-2023).Frontiers in veterinary science · 2025Article
- The biology of the avian influenza virus: A comprehensive review with insights into novel therapeutic strategies.Open veterinary journal · 2025Review
- Pandemic preparedness through vaccine development for avian influenza viruses.Human vaccines & immunotherapeutics · 2024Review
- Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Impact on Pulmonary Influenza.Vaccines · 2024Review
- Production of antiviral "OP7 chimera" defective interfering particles free of infectious virus.Applied microbiology and biotechnology · 2024Article
- Spatiotemporal control of immune responses with nucleic acid cocktail vaccine.Advanced therapeutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A virus is one of the most important zoonotic pathogens that can cause severe symptoms and has the potential to cause high number of deaths and great economic loss. Vaccination is still the best option to prevent influenza virus infection. Different types of influenza vaccines, including live attenuated virus vaccines, inactivated whole virus vaccines, virosome vaccines, split-virion vaccines and subunit vaccines have been developed. However, they have several limitations, such as the relatively high manufacturing cost and long production time, moderate efficacy of some of the vaccines in certain populations, and lack of cross-reactivity. These are some of the problems that need to be solved. Here, we summarized recent advances in the development and application of different types of influenza vaccines, including the recent development of viral vectored influenza vaccines. We also described the construction of other vaccines that are based on recombinant influenza viruses as viral vectors. Information provided in this review article might lead to the development of safe and highly effective novel influenza vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.